KLRC1 and cancer: These agents work by blocking the interactions of PD-1, CTLA-4, NKG2A, TIGIT, etc. with their ligands on cancer cells, releasing the “brakes” of T and NK cells to eliminate cancer cells more efficiently, promoting long-lasting anti-tumor responses (Figure 2).